Healthcare Economist February 2, 2025
Jason Shafrin

Some hints–and only hints–were provided in a CMS press release on Wednesday.

Lowering the cost of prescription drugs for Americans is a top priority of President Trump and his Administration. In accordance with the statutory requirements of the Inflation Reduction Act, the Centers for Medicare and Medicaid Services (CMS) released the list of 15 drugs selected for the second cycle of the Medicare Drug Price Negotiation Program on January 17, 2025. As the second cycle begins under the Trump Administration, CMS is committed to incorporating lessons learned to date from the program and to considering opportunities to bring greater transparency in the Negotiation Program. CMS intends to provide opportunities for stakeholders to provide specific ideas to improve the Negotiation...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, CMS, Congress / White House, Govt Agencies, Insurance, Medicare, Pharma, Pharma / Biotech
A Look at Federal Health Data Taken Offline
ASHP to CMS: 'Change course' on drug pricing
Physicians rally behind Medicare payment bill
What they’re saying about the Medicare Patient Access and Practice Stabilization Act 2025
Supplier Concentration In Medicaid Managed Care: A Cause For Concern

Share This Article